Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma
Status:
Completed
Trial end date:
2021-03-18
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm study designed to evaluate the safety of tezepelumab
administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with
inadequately controlled severe asthma.